Company Overview - Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, specifically for multiple solid tumor indications [1] - The company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor, which has a differentiated mechanism of action compared to other therapies targeting PI3K or mTOR [1] Clinical Trials - A Phase 3 clinical trial, VIKTORIA-1, is currently enrolling patients to evaluate gedatolisib in combination with fulvestrant with or without palbociclib for HR+/HER2- advanced breast cancer [1] - A Phase 1b/2 clinical trial, CELC-G-201, is ongoing to assess gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer [1] - A second Phase 3 clinical trial, VIKTORIA-2, is expected to begin enrolling patients in Q2 2025, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer [1] Investor Engagement - Brian Sullivan, CEO and Co-founder of Celcuity, will present at investor conferences, including the TD Cowen 45th Annual Health Care Conference on March 4, 2025, and the Leerink Global Healthcare Conference 2025 on March 12, 2025 [2]
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences